Table 1

Baseline characteristics of all 13 502 patients in the BSRBR-RA starting a first-line TNFi between 2001 and 2014

All patientsbDMARD refractoryRemaining patients
N13 50286712 635
First TNFi (n=13 502)
 Etanercept4612 (34%)285 (33%)4327 (34%)
 Infliximab3794 (28%)246 (28%)3548 (28%)
 Adalimumab4322 (32%)391 (34%)4031 (32%)
 Certolizumab774 (6%)45 (5%)729 (6%)
Registration year (category) (n=13 502)
 2001–200811 654 (86%)778 (90%)10 876 (86%)
 2011–20141848 (14%)89 (10%)1759 (14%)
Women (n=13 502)10 269 (76%)705 (81%)9564 (76%)
Age (years) (n=13 502)57 (49 to 65)52 (44 to 59)58 (49 to 66)
Age (category) (n=13 502)
 16–503888 (29%)381 (44%)3507 (28%)
 51–909614 (71%)486 (56%)9128 (72%)
Disease duration (years) (n=13 360)10 (5 to 18)9 (4 to 16)10 (5 to 18)
Disease duration (category) (n=13 360)
 0–106835 (51%)494 (57%)6341 (51%)
 11–726514 (49%)368 (43%)6157 (49%)
Concurrent methotrexate (n=13 502)8537 (63%)578 (67%)7959 (63%)
Concurrent steroids (n=13 502)5620 (42%)364 (42%)5256 (42%)
Total comorbidities† (n=13 502)
 None6327 (47%)408 (47%)5919 (47%)
 1 comorbidity4589 (34%)294 (34%)4295 (34%)
 2 comorbidities1894 (14%)122 (14%)1772 (14%)
 3+ comorbidities692 (5%)43 (5%)649 (5%)
Smoking status (n=13 351)
 Current smoker2899 (22%)248 (29%)2651 (21%)
 Ex-smoker5068 (38%)284 (33%)4784 (38%)
 Never smoked5384 (40%)330 (38%)5054 (40%)
Body mass index (kg/m2) (n=11 499*)26 (23 to 30)26 (23 to 31)26 (23 to 30)
Obese (body mass index ≥30) (n=11 499*)2951 (26%)224 (30%)2727 (25%)
Disease activity
 Tender joint count (range 0–28) (n=13 091)15 (10 to 22)16 (11 to 23)15 (10 to 21)
 Swollen joint count (range 0–28) (n=13 083)10 (6 to 15)11 (7 to 16)10 (6 to 15)
 Patient global assessment (range 0–10 cm) (n=13 000)7.5 (6.2 to 8.7)7.8 (6.6 to 9.0)7.5 (6.1 to 8.6)
 ESR (mm/s) (n=12 084*)38 (22 to 62)36 (22 to 60)38 (22 to 62)
 CRP (mm/s) (n=5274*)27 (12 to 57)28 (11 to 56)27 (12 to 57)
 DAS28 (range 0–10) (n=13 255)6.5 (5.8 to 7.2)6.6 (5.9 to 7.3)6.5 (5.8 to 7.2)
 HAQ (range 0–3) (n=12 364*)2.0 (1.6 to 2.4)2.1 (1.8 to 2.5)2.0 (1.6 to 2.4)
SF-36: Physical Component Score‡ (n=8702*)15 (10 to 21)14 (10 to 19)15 (10 to 21)
SF-36: Mental Component Score‡ (n=8702*)42 (34 to 51)40 (32 to 50)42 (34 to 51)
 Index of multiple deprivation
 (excluding Northern Ireland) (n=12 711*)
 Lowest quintile (most deprived)2082 (16%)165 (20%)1917 (16%)
 Middle 3 quintiles8008 (63%)494 (61%)7514 (63%)
 Highest quintile (least deprived)2621 (21%)147 (18%)2474 (21%)
  • Results presented as N (%) or median (IQR).

  • *More than 5% missing data.

  • †Total comorbidities—hypertension, ischaemic heart disease, stroke, lung disease, renal disease, diabetes, depression, liver disease. ‡SF-36; greater score indicates better health.

  • bDMARD, biologic disease-modifying antirheumatic drug; BSRBR-RA, British Society for Rheumatology Biologics Register for rheumatoid arthritis; CRP, C reactive protein; DAS28, 28-joint Disease Activity Score; ESR, erythrocyte sedimentation rate; HAQ, Health Assessment Questionnaire; SF-36, 36-item Short Form Survey for quality of life; TNFi, tumour necrosis factor-alpha inhibitor.